메뉴 건너뛰기




Volumn 119, Issue 15, 2013, Pages 2728-2736

Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia

Author keywords

acute lymphocytic leukemia; inotuzumab; monoclonal antibody; refractory; relapsed

Indexed keywords

AMINOTRANSFERASE; AMYLASE; BILIRUBIN; INOTUZUMAB OZOGAMICIN; TRIACYLGLYCEROL LIPASE;

EID: 84880574025     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28136     Document Type: Article
Times cited : (267)

References (14)
  • 1
    • 0033637411 scopus 로고    scopus 로고
    • Treatment of adult ALL according to protocols of the German Multicenter Study Group for Adult ALL (GMALL)
    • Gokbuget N, Hoelzer D, Arnold R, et al. Treatment of adult ALL according to protocols of the German Multicenter Study Group for Adult ALL (GMALL). Hematol Oncol Clin North Am. 2000; 14: 1307-1325.
    • (2000) Hematol Oncol Clin North Am. , vol.14 , pp. 1307-1325
    • Gokbuget, N.1    Hoelzer, D.2    Arnold, R.3
  • 2
    • 79952095577 scopus 로고    scopus 로고
    • Modern therapy of acute lymphoblastic leukemia
    • Bassan R, Hoelzer D,. Modern therapy of acute lymphoblastic leukemia. J Clin Oncol. 2011; 29: 532-543.
    • (2011) J Clin Oncol. , vol.29 , pp. 532-543
    • Bassan, R.1    Hoelzer, D.2
  • 3
    • 77149133679 scopus 로고    scopus 로고
    • Adult acute lymphoblastic leukemia
    • Faderl S, O'Brien S, Pui CH, et al. Adult acute lymphoblastic leukemia. Cancer. 2010; 116: 1165-1176.
    • (2010) Cancer. , vol.116 , pp. 1165-1176
    • Faderl, S.1    O'Brien, S.2    Pui, C.H.3
  • 4
    • 33645830511 scopus 로고    scopus 로고
    • Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia
    • Thomas DA, Faderl S, O'Brien S, et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer. 2006; 106: 1569-1580.
    • (2006) Cancer. , vol.106 , pp. 1569-1580
    • Thomas, D.A.1    Faderl, S.2    O'Brien, S.3
  • 5
    • 33750349299 scopus 로고    scopus 로고
    • Rituximab in the treatment of adult ALL
    • Gokbuget N, Hoelzer D,. Rituximab in the treatment of adult ALL. Ann Hematol. 2006; 85: 117-119.
    • (2006) Ann Hematol. , vol.85 , pp. 117-119
    • Gokbuget, N.1    Hoelzer, D.2
  • 6
    • 81355128224 scopus 로고    scopus 로고
    • Efficacy and toxicity of rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or Burkitt-like leukemia/lymphoma: Cancer and Leukemia Group B (CALGB) study 10002 [abstract]
    • Abstract 858
    • Rizzieri D, Johnson J, Byrd J, et al. Efficacy and toxicity of rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or Burkitt-like leukemia/lymphoma: Cancer and Leukemia Group B (CALGB) study 10002 [abstract]. Blood (ASH Annual Meeting Abstracts). 2010; 116. Abstract 858.
    • (2010) Blood (ASH Annual Meeting Abstracts) , vol.116
    • Rizzieri, D.1    Johnson, J.2    Byrd, J.3
  • 7
    • 77956240944 scopus 로고    scopus 로고
    • Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de-novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia
    • Thomas D, O'Brien S, Faderl S, et al. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de-novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. J Clin Oncol. 2010; 28: 3880-3889.
    • (2010) J Clin Oncol. , vol.28 , pp. 3880-3889
    • Thomas, D.1    O'Brien, S.2    Faderl, S.3
  • 8
    • 84880574060 scopus 로고    scopus 로고
    • Immunochemotherapy with rituximab improves molecular CR rate and outcome in CD20+ B-lineage standard and high risk patients; Results of 263 CD20+ patients studied prospectively in GMALL study 07/2003 [abstract]
    • Abstract 170
    • Hoelzer D, Huettmann A, Kaul F, et al. Immunochemotherapy with rituximab improves molecular CR rate and outcome in CD20+ B-lineage standard and high risk patients; results of 263 CD20+ patients studied prospectively in GMALL study 07/2003 [abstract]. Blood (ASH Annual Meeting Abstracts). 2020; 116. Abstract 170.
    • (2020) Blood (ASH Annual Meeting Abstracts) , vol.116
    • Hoelzer, D.1    Huettmann, A.2    Kaul, F.3
  • 9
    • 49249109608 scopus 로고    scopus 로고
    • Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: A Children's Oncology Group pilot study
    • Raetz E, Cairo M, Borowitz M, Blaney S, et al. Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group pilot study. J Clin Oncol. 2008; 26: 3756-3762.
    • (2008) J Clin Oncol. , vol.26 , pp. 3756-3762
    • Raetz, E.1    Cairo, M.2    Borowitz, M.3    Blaney, S.4
  • 10
    • 79959312575 scopus 로고    scopus 로고
    • Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival
    • Topp M, Kufer P, Gokbuget N, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol. 2011; 29: 2493-2498.
    • (2011) J Clin Oncol. , vol.29 , pp. 2493-2498
    • Topp, M.1    Kufer, P.2    Gokbuget, N.3
  • 11
    • 0033673757 scopus 로고    scopus 로고
    • Understanding and exploiting nature's chemical arsenal: The past, present and future of calicheamicin research
    • Thorson J, Sievers E, Ahlert J, et al. Understanding and exploiting nature's chemical arsenal: the past, present and future of calicheamicin research. Curr Pharm Des. 2000; 6: 1841-1879.
    • (2000) Curr Pharm Des. , vol.6 , pp. 1841-1879
    • Thorson, J.1    Sievers, E.2    Ahlert, J.3
  • 12
    • 84862786326 scopus 로고    scopus 로고
    • Inotuzumab ozogamicin, an anti-CD22-calicheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: A phase 2 study
    • Kantarjian H, Thomas D, Jorgensen J, et al. Inotuzumab ozogamicin, an anti-CD22-calicheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Lancet Oncol. 2012; 13: 403-411.
    • (2012) Lancet Oncol. , vol.13 , pp. 403-411
    • Kantarjian, H.1    Thomas, D.2    Jorgensen, J.3
  • 13
    • 58149394138 scopus 로고    scopus 로고
    • Outcome of adults with acute lymphocytic leukemia after second salvage therapy
    • O'Brien S, Thomas D, Ravandi F, et al. Outcome of adults with acute lymphocytic leukemia after second salvage therapy. Cancer. 2008; 113: 3186-3191.
    • (2008) Cancer. , vol.113 , pp. 3186-3191
    • O'Brien, S.1    Thomas, D.2    Ravandi, F.3
  • 14
    • 0033214233 scopus 로고    scopus 로고
    • Primary refractory and relapsed adult acute lymphoblastic leukemia
    • Thomas D, Kantarjian H, Smith T, et al. Primary refractory and relapsed adult acute lymphoblastic leukemia. Cancer. 1999; 86: 1216-1230.
    • (1999) Cancer. , vol.86 , pp. 1216-1230
    • Thomas, D.1    Kantarjian, H.2    Smith, T.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.